Keenan Greg 4
4 · Aurinia Pharmaceuticals Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Keenan Greg
SVP, Chief Medical Officer
Transactions
- Award
Common Stock
2025-02-28+62,583→ 174,028 total - Sale
Common Stock
2025-03-03$8.00/sh−12,239$97,912→ 161,789 total - Award
Employee Stock Option (right to buy)
2025-02-28+95,570→ 95,570 totalExercise: $7.55Exp: 2035-02-28→ Common Stock (95,570 underlying)
Footnotes (4)
- [F1]Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
- [F2]Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the January 30, 2024 grant.
- [F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.